UBS Downgrades Crinetics Pharmaceuticals to Neutral, Raises Price Target to $85
Crinetics Pharmaceuticals Inc CRNX
$83.52
▼ -0.13%
($-0.11)
⬆️ Above Yest. High
📅 Earnings This Week
Open
$83.75
Prev Close
$83.63
Day Range
$83.47 – $83.80
52W Range
$25.83 – $84.00
Market Cap
$8.85B
Beta
0.10
EPS (TTM)
$-5.13
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-07-18 |
| Shares Out. | 105,840,000 |
| Website | crinetics.com/ ↗ |
| Phone | 18584506464 |
| Employees | 594 |
| Revenue | $10.7M |
| Gross Profit | $10.5M |
| Net Income | -$127.8M |
| Free Cash Flow | -$419.5M |
| Total Assets | $1.40B |
| Total Liabilities | $120.7M |
| Equity | $1.28B |
About Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Crinetics Pharmaceuticals Inc is a publicly traded company under the ticker symbol CRNX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
22 analysts (2026-07-01)